Adaptive Biotechnologies Corporation (ADPT) Earnings Call Transcript & Summary

November 4, 2026

NASDAQ US Health Care Life Sciences Tools and Services earnings 45 min

Earnings Call Speaker Segments

Karina Calzadilla

executive
#1

Thanks, Daniel, and good afternoon to all of you. It's my pleasure to welcome everyone to Adaptive Biotechnologies' Third Quarter 2026 Earnings Conference Call. We released a press release earlier today that reports Adaptive's financial results for the third quarter of 2026. You can find that press release at www.adaptivebiotech.com. This call is being webcast live, and we'll be referring to a slide presentation that's been posted in the Investor section of our corporate website. During today's call, management will make projections and other forward-looking statements, as defined under federal security laws, about future events and the company's future financial performance. These statements reflect management's current view of the business as of today. Actual results could differ materially from today's forward-looking statements based on a number of factors, which are described in our public filings with the SEC and listed in this presentation. Also, we will discuss non-GAAP financial measures during the call, and a reconciliation from non-GAAP to GAAP metrics is available in our earnings release. With us today are Chad Robins, our CEO and Co-founder, and Kyle Piskel, our Chief Financial Officer. Other members of management will be available for Q&A. With that, I'll hand the call over to Chad. Chad?

Chad Robins

executive
#2

Thanks, Karina. Good afternoon, and I appreciate everyone joining us for our third quarter earnings call. For Adaptive, Q3 represented a breakthrough quarter. We reached profitability at the total company level sooner than expected while still delivering rapid MRD growth. MRD revenue, excluding milestones, rose 44% year-over-year, powered by clinical testing volume and pharma sequencing revenue. Total company gross margin came in at 76%, we generated $8 million in free cash flow, and we closed the quarter with roughly $386 million in total cash. What these results show is that we have been building toward a business that pairs rapid growth with a strong financial profile. Reaching profitability is the product of years spent executing with discipline, allocating capital thoughtfully, and making focused investments in sustainable growth. The opportunity in front of us continues to grow. Revised guidelines and a new definition of cure in multiple myeloma give clonoSEQ a stronger clinical foundation. Because clinical volumes and pharma revenue came in above what we expected, we are once again lifting our full year 2026 MRD revenue guidance. On the Immune Medicine side, we are collaborating closely with Morgan Stanley to advance the separation process and remain on track to announce the path forward by year end. In the quarter, the business also received a milestone payment from Pfizer after successfully delivering rheumatoid arthritis data under our agreement — an important accomplishment for the team. Turning to slide four, let's examine MRD, our clinical business, more closely. Q3 saw clinical testing volume stand out, climbing 46% compared with a year earlier and fueling a 41% increase in clinical revenue. Close to 40,000 clonoSEQ tests were delivered, a sequential gain of 10%, which works out to roughly 3,500 more tests. Growth came from every reimbursed indication. DLBCL posted the strongest sequential gain at 20%, and multiple myeloma, representing 45% of volume, was up 11%. To drive and sustain this growth, our commercial team is executing on several fronts. These priorities include expanding blood-based testing, boosting community adoption, and embedding clonoSEQ into clinical workflows; we made progress on all three during the quarter. Blood-based testing rose 68% year-over-year and 12% sequentially, making up 51% of total clonoSEQ volume. For myeloma monitoring, 31% of MRD testing is now done through blood-based assays, which gives physicians an easier way to track patients over time. Sequentially, community volume rose 14%, growing faster than academic centers. A year ago community practices accounted for 31% of total volume; that figure now stands at 37%, which extends clonoSEQ's reach to more patients, and we are also simplifying how testing is ordered and repeated. EMR-integrated accounts now generate close to half of our orders, and our team is focused on adding integrations as well as driving utilization higher. Among Flatiron-integrated community accounts, 78% of serial monitoring orders that are due have been fulfilled, which shows follow-through on planned patient monitoring. Our clinician base is growing in community and academic settings alike. Roughly 5,600 clinicians placed orders for clonoSEQ during Q3 — a 37% rise compared with the same period last year — and those clinicians account for around 40% of hematology oncology providers in the U.S. That breadth highlights how MRD is playing a larger part in clinical care. With adoption growing and doctors checking on patients more often, we're pushing our reimbursement efforts forward to back that usage. Moving to slide five: U.S. ASP for Q3 was $1,380, up 3% year-over-year and essentially level with the previous quarter. Our expectation for the full year remains an average ASP of roughly $1,400, and we see distinct catalysts pulling us toward our longer-range goal of $1,700 to $1,800 per test. I'll start with the coverage improvements we secured this quarter. We broadened commercial coverage in DLBCL and MCL, two indications where reimbursement opportunity is substantial. Within DLBCL, Avalon and Concert were added. Within MCL, we added Avalon, Blue Cross Blue Shield, and UnitedHealthcare; Medicaid coverage was also extended into Illinois and Ohio, and we have now secured coverage in states accounting for roughly 62% of our Medicaid testing volume. Although Medicaid makes up about 10% of our payer mix and is still the segment that pays us least, these coverage wins are producing results. Medicaid ASP rose 26% year-over-year. The biggest opportunity in front of us is Medicare and Medicare Advantage, which now account for roughly 45% of our payer mix, compared with 39% a year ago. On this front, testing more frequently plays a key part in the ASP story. The current Medicare episode rate bundles up to four tests across a patient's lifetime. As physicians monitor more patients more often, a growing share is going beyond those four tests, which pressures realized ASP; we observed this dynamic during Q3, especially in multiple myeloma, our largest indication. That said, supporting this testing also let us build the evidence needed to pursue expanded coverage. We have now filed our technical assessment with MolDX for an additional maintenance testing bundle in multiple myeloma, and discussions are actively underway. This stands as our priority catalyst, with recent NCCN guideline updates further reinforcing the clinical rationale behind our submission. In addition to the maintenance bundle for myeloma, we're working to secure coverage for recurrence monitoring in a number of indications. Coverage for recurrence monitoring already exists in MCL, and we plan to file for CLL in the first half of next year, and we're currently generating data in multiple myeloma as well. We remain highly confident in the $1,700-$1,800 ASP opportunity. Clinical adoption continues to grow, and we have targeted coverage efforts underway to turn that adoption into wider reimbursement. Let's now turn to slide six and the multiple myeloma progress that supports both this strategy and clonoSEQ's longer-term potential. This quarter brought two significant developments that strengthen the groundwork for MRD testing in multiple myeloma, which is our biggest indication in both clinical testing and pharma. First, the revised NCCN guidelines now place greater emphasis on MRD testing and provide more detailed guidance. A dedicated page covering the principles of MRD testing appears in the guidelines for the first time. They call for an FDA-approved assay like clonoSEQ, which is named specifically and identified at 10 to the minus six—one cancer cell among a million cells—as the preferred sensitivity, given its stronger prognostic value. clonoSEQ is, in fact, the only assay that can deliver sensitivity of 10⁻⁶ sensitivity with the scale required for broad clinical use; this is meaningful recognition of the rigor that clonoSEQ brings to MRD assessment. Those guidelines also lay out specific time points for testing during maintenance and surveillance, which strengthens the case that MRD matters beyond just the initial treatment response. For community oncologists especially, having clear guidance on when and how to test can help turn clinical evidence into more consistent use. Importantly, the guidelines now cover MRD-guided therapy, noting that MRD negativity can inform shared decisions about treatment intensity, while rising MRD may prompt greater vigilance and monitoring. The second item is equally important: a new cure definition that was shared on behalf of the International Myeloma Working Group at the International Myeloma Society annual meeting. Under that definition, patients must be off treatment for five years with sustained MRD negativity, confirmed by a minimum of four negative assessments and no positive MRD results. Testing has to rely on next-generation sequencing or next-generation flow at a sensitivity of 10⁻⁶. Here too, clonoSEQ stands alone as the only assay capable of performing at that scale. The implications are substantial. Determining which patients satisfy this definition depends on repeated, highly sensitive MRD assessment. Because clonoSEQ matches the cure definition's requirements directly, it gives further support to our recurrence monitoring strategy. Taken as a whole, these advances strengthen the case for how MRD ought to be quantified and for tracking it across time.

Chad Robins

executive
#3

We're encouraged to see systematic MRD assessment taking on a more central role in the way the field judges whether treatment succeeds. That emphasis on responses that go deeper and hold up over time is likewise influencing how drugs get developed. Turning to slide 7, let's look at our MRD pharma business. This segment just posted one of its best quarters in years, fueled by faster uptake of MRD in drug development, especially in multiple myeloma. Excluding milestones, revenue from the underlying sequencing business rose 55% versus the prior year, and for the full year we now anticipate pharma sequencing growth of roughly 25%. During the quarter we brought in 27 studies that were new or amended, which lifts our portfolio to 191 active studies worldwide. Backlog came in at about $270 million, a 34% increase year over year, which gives us visibility into future revenue and reflects ongoing demand from our biopharma partners. Roughly 60% of active studies and 65% of backlog involve multiple myeloma. That indication drove 79% of new bookings this quarter. Several important trends are behind this exceptional growth in multiple myeloma. To begin with, the January draft guidance from FDA on using MRD as an accelerated endpoint clearly signaled regulatory acceptance; we now have 19 multiple myeloma studies employing MRD as a primary endpoint, compared with 12 a year earlier. On top of that, the new definition of cure brings yet another dimension to the opportunity. Already, multiple myeloma trials are adding more testing time points so that a cure fraction can be assessed, which pushes bookings per study higher. Our partners are further exploring how MRD might guide treatment itself. clonoSEQ now appears in 23 interventional studies, spanning multiple myeloma, CLL, and ALL, which helps build the evidence for treatment decisions directed by MRD. For our pharma business, this opens opportunities via additional studies that use MRD as an endpoint, more assessments across time, and a growing part in guiding therapy. In both clinical and pharma, Q3 showed the commercial strength of clonoSEQ. Progress in evidence, guidelines, and trial design strengthens our confidence in what lies ahead. I'll hand things to Kyle now for a review of our financial results. Kyle?

Kyle Piskel

executive
#4

Thanks, Chad. On slide eight I'll go through the third-quarter results. As a reminder, the Genentech payment amortization inside Immune Medicine is left out of every prior-period comparison. Total revenue was $83.9 million, up 39% from a year earlier, driven by MRD growth and by revenue from our Pfizer rheumatoid arthritis agreement in Immune Medicine. MRD represented 86% of total company revenue. MRD revenue reached $72.6 million, a 28% increase year-over-year. Excluding $6.5 million of milestone revenue recognized in last year's third quarter, core MRD revenue rose 44%. Clinical and pharma represented 75% and 25% of MRD revenue, respectively. Revenue from Immune Medicine came to $11.3 million, driven primarily by our target discovery agreement with Pfizer. On margins, sequencing gross margin—leaving out MRD and Immune Medicine milestones—climbed to 73%, compared with 66% in the prior-year period. For MRD sequencing, gross margin stood at 74%. That improvement reflects efficiencies in the lab now that we've moved to NovaSeq X, along with operating leverage gained from higher testing volumes. Total operating expenses, cost of revenue included, reached $84.4 million, a 1% increase year-over-year. We kept investing in our commercial infrastructure—reimbursement and EMR integration initiatives among them—and that was partly offset by reduced R&D spending in Immune Medicine. Looking at our segments, MRD Adjusted EBITDA climbed to $15.1 million, up from $7 million in the prior-year period, driven by both robust revenue gains and ongoing operating leverage. For the quarter, Immune Medicine Adjusted EBITDA came in at $3.2 million. On a total company basis, Adjusted EBITDA was positive at $14.3 million — a major milestone that speaks to our growth and disciplined spending. GAAP net income for the quarter reached $2.8 million. That's another notable win, though at present we don't expect GAAP net income or positive EPS in Q4 or for the full year. Let's move to slide nine for our updated guidance. We are lifting our full-year MRD revenue outlook to $276 million-$286 million, compared with the earlier $268 million-$278 million range. The bump comes from stronger-than-anticipated clinical volume and pharma sequencing results in Q3, plus we now expect year-over-year clinical volume growth of about 42%, above the previous 38%-40% guidance. Our outlook still incorporates $9 million in MRD milestone revenue, all of which was booked in the first quarter, and we assume no further milestone revenue for the rest of the year. At the midpoint, the new guide implies 32% year-over-year MRD revenue growth, or 41% when milestones are excluded. For the entire year, we now anticipate operating expenses to come in around $350 million—that's the bottom of the $350 million to $355 million range we gave earlier, and roughly 5% higher than the prior year. We're achieving stronger growth while still keeping a tight grip on costs. With that said, I'll hand things back to Chad.

Chad Robins

executive
#5

Thank you, Kyle. As we head into Q4, we're seeing growth across the board, profitability that has come in above what was expected, and an improved revenue forecast for the entire year. Our submission for the maintenance bundle now sits with MolDX, and we're holding active talks about this catalyst, which could be quite meaningful in broadening reimbursement for ongoing testing. Meanwhile, progress on guidelines, the definition of cure, and drug development is raising the importance of MRD and widening clonoSEQ's potential over the long term. Profitability marks an exciting turning point for our company, letting us put more resources into strengthening our competitive edges and into seizing the substantial growth opportunities that lie ahead. With that, operator, let's open the line for questions.

Thomas Von Der Vellen

analyst
#6

Hey, everyone. Thomas here, filling in for Subbu. Appreciate you taking our questions.

Chad Robins

executive
#7

Of course.

Thomas Von Der Vellen

analyst
#8

On the CMS rates that have been drafted for 2027, could you speak to the exposure for clonoSEQ given how your Medicare and non-Medicare volumes currently split, and how that could affect ASP in the near term, or whether you have levers available to offset any pressure and stay on track with your ASP targets?

Kyle Piskel

executive
#9

Sure, I'll cover CMS, the PLA code, and the PAMA legislation. As a bit of a reminder, early in the year we concluded that we did not qualify as an applicable laboratory under the PAMA regulations, so we did not submit any private payer data to CMS in connection with that. Once CMS released the preliminary rates, we found that erroneous data had been submitted on the clonoSEQ PLA, and we know this because no other laboratory is able to perform that test. A quick reminder on why we don't qualify as an applicable laboratory: it comes down to the episodic billing structure with Medicare. The bulk of our Medicare revenues is derived from the bundled structure. Again, when we discuss the insulation for the business, our view is that the PLA rate-setting process ought not to have any pull-through into the episodic framework. Separately, with CMS, we are working to rectify and correct the erroneous data, and we've made it clear to CMS that we do not believe they should be relying on any erroneous data to set a price point for the clonoSEQ PLA code. So we expect to have that resolved before the finalized rates, which should take effect sometime in November, based on our understanding with CMS. We stay confident in the long-term pricing strategies we have in play, and that confidence is only reinforced by the progress we're making with our contracted payers, the rates we have in place, and our structure with MolDX.

Thomas Von Der Vellen

analyst
#10

Thanks, and congrats on another solid quarter. It's impressive that so many key growth drivers are firing at once. Looking toward 2027, what do you see as the single biggest lever to move clonoSEQ into its next growth phase? Would it be blood? EMR pull-through? As people start to underwrite that growth, how should we think about the most critical pieces for next year? Thank you so much.

Susan Bobulsky

executive
#11

Sure, and thanks for asking. While we aren't providing guidance for 2027, I definitely see every reason to expect that we'll continue growing at a very high rate in 2027 and beyond. We still have a high ceiling; we intend to keep focusing on many of the same drivers that have brought us to where we are today. I think the foundations of that growth in 2027 will really be the data and the guidelines. The guidelines have been very favorable for MRD and for clonoSEQ specifically over the last 18 months, and there are many opportunities to pull through those updates in the clinic; they also will be favorable for our pharma business, as a side note, because the definition of cure in multiple myeloma will help drive increasing long-term testing time points so that pharma companies can assess their drug's efficacy in the context of cure. The data is going to keep evolving. There's a lot of excitement on our side about what you'll be seeing at ASH, which is only about six weeks away. We can go into more detail on that at a later point. Beyond those two foundations, the growth drivers we concentrate on are the same ones we've consistently discussed: EMR integration, blood-based testing, and community expansion. In many respects, these reinforce each other; we began working on EMR a few years back, and we have integrated a large number of our key accounts, yet that's not where it ends, since a major priority moving forward is making the most of how those integrations get used—especially to support serial testing. We've observed substantial pull-through rates when it comes to serial testing through our Flatiron oncology EMR rollout. Blood-related volume keeps climbing. We're putting money into product development there so the blood products perform better. Community now accounts for 37% of our volumes, and the guidelines will boost our capacity to educate and encourage consistent testing throughout community practices. So we still anticipate robust growth in 2027 and afterward, and it will come from a mix of all those elements.

Casey Woodring

analyst
#12

Great. Thanks for taking my questions. So I guess the first one — it looks like DLBCL had the strongest sequential clinical volume growth. There's been a bit of competitive noise in that area. Could you share what you're hearing from customers and talk about your competitive moat in DLBCL going forward, and whether you'd expect that to remain the strongest sequential driver of volumes moving forward?

Susan Bobulsky

executive
#13

Yes, our sequential growth in DLBCL has stayed very strong and quite consistent from quarter to quarter, and I expect we'll keep delivering consistent double-digit growth rates on an ongoing basis. Competitors do come up in conversation, yet our footing for continued growth is quite solid. That strength rests on several things: the assay itself, purpose-built for blood cancers such as lymphomas; the broad reimbursement already in place for our test in lymphoma; our capacity to keep drawing on real-world data; and the roughly 9,000 patients tested with clonoSEQ so far. Given all of that, plus the relationships we've built with key customers and the satisfaction we keep delivering them, I feel very confident about where we stand in this field. Ultimately, this market remains severely under-penetrated, so the chatter generated when more firms discuss MRD and DLBCL helps—and helps us disproportionately, given our position as market leader. We're eager about the data we'll keep pushing forward in this area, and I believe you'll see a solid amount of it at ASH this year. We think we're well positioned near term by capitalizing on our moats and on the buzz surrounding MRD, and over the longer term too, where we're confident our technology's performance will ultimately prevail.

Casey Woodring

analyst
#14

Understood, that's useful. I believe you touched on this in response to an earlier question, but 64% of the rise in your MRD pharma backlog came from multiple myeloma. Does that tie to guideline revisions or the new cure definition, or, more broadly, what is fueling the momentum in multiple myeloma at the moment?

Susan Bobulsky

executive
#15

Yes, a few different factors explain the gains we're seeing in our myeloma pharma business. First, earlier this year, the accelerated endpoint that ODAC adopted back in 2024 — the FDA actually put out draft guidance to really solidify use of that endpoint. A number of pharma companies, I think, viewed that as an important signal to proceed with new primary endpoint studies, and we've seen quite a few new primary endpoint studies in 2026. Second, the cure definition issued by the IMWG and IMS roughly a month ago. Many of our pharma clients had been expecting that. KOLs have been discussing it for a number of months, so studies being designed today are building in more time points, as I mentioned earlier, so they can make that cure claim for the therapeutics being evaluated in the study, and that is producing higher bookings and more time points. Finally, there's simply the growth in regulated and interventional use. We now have 23 additional studies, including eight multiple myeloma. Regulated studies now make up the majority of our trials, so overall we're seeing that MRD is simply becoming the standard for how studies are conducted in multiple myeloma, and we believe that will keep contributing to strength for our pharma business going forward.

Casey Woodring

analyst
#16

Great. Thank you so much.

Chad Robins

executive
#17

Thanks, Casey.

David Westenberg

analyst
#18

Hi, and thanks for taking my question. I also wanted to dig into the DLBCL momentum. It was up 20% quarter over quarter and is still a fairly under-penetrated opportunity. What were the main things that drove DLBCL up 20%, and how should we view it as a growth contributor over the coming years? Should we think of DLBCL as really the dominant, accretive growth driver in 2027 and 2028?

Susan Bobulsky

executive
#19

Yeah, David, thanks for the question. Like you mentioned, we've been quite pleased with DLBCL growth, which keeps outpacing every other indication, and that growth is broad-based; it's coming from community as well as academic accounts. Lately we've had particular success driving greater adoption in some of the biggest community practice networks. A good chunk of our largest DLBCL growth this past quarter came from one of the biggest networks in the country. All of this stems from our continued focus on market development. We have to educate on what role MRD plays, how it can augment and improve upon PET scans and other more traditional ways of thinking about disease burden, and how it can inform treatment. There are a number of studies underway now, and a few even reading out at ASH, showing various ways MRD can be useful in informing treatment selection and escalating or de-escalating therapy in DLBCL. We still expect it to be a top growth driver over the next few years, especially given the investments we're making in data and the potential for pharma to expand its investment in MRD-guided therapy trials going forward.

Chad Robins

executive
#20

But David, while multiple myeloma has been a big growth driver, it's still going to be a major contributor to our growth, especially with the updated guidelines and the new definition of cure. Just to kind of elevate this for a minute, I mean, it's hard to kind of grasp how significant this is. We believe this is the first cure definition based on an NGS test. Basically, what they're saying is if you're MRD negative using clonoSEQ across kind of four different tests, then you're cured of a disease. Just as an anecdote, we had investigators when they learned this, crying in the hallway, who had been working on it for more than a decade. Myeloma is going to keep accelerating.

David Westenberg

analyst
#21

Understood; with that, I’d like to move straight ahead and dive in—thanks for adding that extra color. I want to focus on the $1,400 ASP target. I believe you came in and mentioned $1,386. How much of that comes from blocking and tackling versus some of the new adds you referenced, the new coverage adds you referenced? It’s November of this time, so to reach that $1,400, do you need any particular timing around coverage to get there? I’ll leave it there. Thanks again.

Kyle Piskel

executive
#22

Yes, thanks for the question, David. This is Kyle. Blocking and tackling definitely factors into every quarter. In my view, blocking and tackling contributes even in the fourth quarter. Of course, when we consider the guide and the rest of the year, one element is frequency uptake related to Medicare and the pressure we’re seeing there, which in the end is a positive thing. I think there are some timing dependencies that could shift the needle either way, but at the foundation, I think we’re in a good spot, and there are some timing considerations, but we’ll see how those unfold, yet we’re confident in the long-term trajectory here and remain confident about reaching that $1,400 at some point.

Chad Robins

executive
#23

Yeah, David, let me jump in and offer a bit of color and context here. Some of that ASP pressure you're seeing is actually working in our favor, and it's what we're leveraging for our MolDX submission. If you look at our overall strategy, it helps to think about a patient's treatment journey as having three distinct phases. The first one is the active treatment phase, and Medicare already reimburses us for four tests there, right? The second phase—and this is what we've already submitted and are in active, very positive discussions with MolDX about—is what we're calling the maintenance treatment phase. We've submitted for an additional bundle of five tests. This is the first time I've actually said that publicly, but yes, we have submitted for five more tests in the maintenance setting. The third phase is recurrence monitoring. We also mentioned on this call, in multiple myeloma, that in the second half of this year we believe we'll have data for recurrence monitoring. So that really covers all three phases of treatment—of a patient's care continuum. Again, I think it's not a question of if—we believe it's a question of when. I'd say we're highly encouraged by the discussions we've had that there will be an upcoming catalyst when we secure this maintenance bundle. I do want to be clear, though: we can't guarantee the number of tests in the bundle. We can't guarantee timing. What I can guarantee—what I can tell you—is that the discussions have been very, very positive. There's recognition that this is necessary, and it aligns really well with the new NCCN guidelines and the new definition of cure. So all these factors are converging to indicate that you need to monitor patients more frequently across all phases of this care continuum. So that's really just to give you perspective on how all of this fits together within our broader reimbursement strategy, so we're not thinking short-term. We do believe we'll be at approximately $1,400 this year. On timing, we may see some very slight variation or fluctuation, but what we've seen—and we have more confidence than ever, based on the discussions we're having—is that our ASP targets of $1,700 to $1,800, we won't just hit them; we believe we will hit them, and we could potentially even accelerate that timeframe in some cases.

David Westenberg

analyst
#24

Thanks.

Dan Brennan

analyst
#25

Great, thank you. I appreciate the questions, and congratulations on the quarter. Turning to pharma, the numbers were strong once again. Could you give us a sense of what is driving the pharma side of the business? What is assumed for the fourth quarter? And could you refresh us on the milestone opportunities ahead — perhaps not this year but further out — as in, which milestones over the next 12 months might be realistic?

Kyle Piskel

executive
#26

Yes, Dan, thanks for asking. We're genuinely thrilled about what we're seeing in pharma bookings and backlog growth, along with the < > during Q3. Revenue can be uneven when you compare one quarter to the next, as you're aware, but considering the longer-term opportunity and the expansion in that business, backlog closed Q3 at $270 million versus $200 million the prior year, which really positions us for strong growth. Excluding milestones, we now expect 25% year-over-year growth in the pharma business. That puts us in a good spot as we head into 2027. On the milestones front, we indicated that we lack any visibility into Q4 regarding milestones. And once more, we consider that matter when we gain line of sight. We will revise our guidance accordingly. That timing isn't necessarily something we control, though we still hold a healthy backlog of milestone opportunities that could read out; predicting and modeling when that happens is simply very difficult. We continue to expect some of those to appear over the next several years as well. We'll share additional detail on this during the next earnings call.

Susan Bobulsky

executive
#27

I want to jump in briefly on the dynamics here that really matter. To restate the point, the FDA draft guidance issued earlier this year, the definition of cure—which pushes companies toward longer studies with additional time points—and the interventional nature of many study designs, all of that, together with the fact that we hold the only FDA-cleared assay and have a strong reputation and relationship with these companies for delivering registrational-grade data over many years, means I think we remain in a really strong position to support what myeloma drug development programs need for years ahead.

Dan Brennan

analyst
#28

Great. And on volumes — terrific volume once more. For a while now you've been posting numbers in the 30s and low 40s. Market penetration still doesn't look all that high. You've got all these drivers lined up ahead of you. How should we think about this, as we move into 4Q and then roll into 2027 — most of us naturally assume volumes decline. You aren't giving 2027 guidance at this point, but the business still seems to carry so much momentum. Is there any way to frame what volumes might be, say, looking past 2026 toward 2027 — what framework could we use?

Chad Robins

executive
#29

Dan, obviously we're not yet in a position to guide on 2027. What I can tell you is that our team has a tremendous amount of internal excitement in the conversations they're having with clinicians about the new definition of cure. The updated NCCN Guidelines have provided a great call point, especially in the community, where doctors are much more apt to follow guidelines. I'll just say we expect that momentum to keep going. We don't see anything slowing this down. If anything, I think there have been two meaningful updates across the industry overall, which further support the growth trajectory ahead and give us confidence in it.

Dan Brennan

analyst
#30

Awesome. Thanks, Chad.

Chad Robins

executive
#31

Thank you.

Mark Massaro

analyst
#32

Hey, guys. Thanks for taking the questions, and some of us are jumping between calls tonight, so forgive me if this has already been asked; now that you've reached profitability across the whole company, should we expect any possible shifts in capital deployment as we look toward 2027? Also curious, at a very high level, what your thinking is on the possibility of pursuing tuck-ins, assuming they made sense and were disciplined. Just wanted to get a feel for how you're approaching capital deployment now that you're a profitable company.

Chad Robins

executive
#33

Yeah. I'll ask Susan to begin with the areas we're investing in MRD, then I'll offer some broader remarks about a few things we're considering.

Susan Bobulsky

executive
#34

So we've been expanding quickly for a number of years now, and there's still a substantial ceiling for us to keep growing into. As profitability comes, I believe the smartest move is to put those profits to work expanding our moats further and lifting the trajectory of MRD adoption. Starting this year, we've been quite focused on pinpointing strategic areas for investment. In 2025, our investing has centered on building capabilities across a few key areas. Real-world data is one; AI and AI-driven business process automation specifically; our revenue cycle management; and creating the next generation customer experience, with emphasis on making serial testing easier. We achieved considerable progress across all four of these areas this year, and we plan to keep up those investments in 2027. I should also point out that we have a strong R&D effort, through which we're investing in enhancing current products and advancing new ones so we extend our leadership in the spaces where we already play, and also look at ways we can either leverage our channel or develop new applications of our proprietary platform.

Chad Robins

executive
#35

Right. And again, one point worth stressing — Susan brought up improving how our current clonoSEQ performs so we can deepen heme MRD, plus using our heme channel to deliver other things you might be able to do with that patient sample. But the third area we're actively developing is new uses of our immunosequencing platform aimed at unmet medical needs outside hematology. There are some genuinely intriguing potential applications of our platform that we're looking into. Again, we're not ready to discuss them on this call, but I think they could be quite interesting, fairly large opportunities to build on what we already have — both our platform technology and the infrastructure we've put in place around how to deliver, how to get pet tests reimbursed, revenue cycle management, and everything else you need to handle as a diagnostic company.

Mark Massaro

analyst
#36

All right, that's great. Then I wanted to ask about the NCCN guideline recognition. What's your thinking there — you're already the dominant market leader, so some of us wonder how this works, because usually when you're number one, you can't do better than number one, but maybe you could accelerate; it's typically rare for market leaders who've been in the space a while to speed up; so I'm curious what benefits you see coming from the NCCN recognition and, in particular, clonoSEQ being called out.

Susan Bobulsky

executive
#37

Yeah, so as was said earlier, the biggest opportunity is in community oncology, where guidelines matter especially. Clinicians really want us to tell them how and when to test. So we're very actively promoting the guideline updates right now and seeing a lot of engagement from clinicians. One thing that matters to us in the community is finding ways to help practices align with those guidelines so testing becomes more consistent across all the patients they see. That ties into our EMR integration strategy and thinking about how we can build standardized testing pathways and protocols, taking accounts that are doing this successfully and bringing their stories to share with other accounts; so that's the work underway at the moment. I do think it's a potentially meaningful accelerator for the myeloma business. Importantly, it also supports the maintenance bundle submission currently with MolDX, which will be an important future driver of ASP; so we have a number of opportunities folded into these guidelines; it's also notable that the guidelines, combined with the cure definition, really underscore the need for bone marrow testing, and I actually believe there's an opportunity to increase community testing to use bone marrow as a complement to blood, in areas where they may not be doing so today. We're eager to work with them to help ensure they can deliver the potential of a cure to as many patients as possible, and to do that, they need to incorporate clonoSEQ MRD testing in marrow as well as in blood.

Mark Massaro

analyst
#38

Awesome. Thanks so much for the time, guys.

Operator

operator
#39

Thanks. At this point, I see no additional questions. That brings today's conference call to a close. We appreciate everyone joining us. You're free to disconnect now.

Read the full transcript via the API

You're viewing the first half of this call. Get the complete Adaptive Biotechnologies Corporation transcript — plus 132,000+ transcripts from 7,000+ companies, speaker segments, AI summaries and full-text search — through the EarningsCalls.dev API.

Get the API View API docs →

For developers and AI pipelines

Programmatic access to Adaptive Biotechnologies Corporation earnings transcripts and 132,000+ others is available through the EarningsCalls.dev REST API. Plans from $39.99/month — full transcripts, speaker segments, full-text search, and the recently-added /api/v1/transcripts/recent polling endpoint for ETL pipelines.

More tools for stock research

OptionsBell: an unusual options activity scanner that tracks options flow across all US stocks and emails you when large trades appear in Adaptive Biotechnologies Corporation or any ticker on your watchlist.

StockMarketScan: a stock screener with alerts: 24 pre-built screens refreshed every 5 minutes, watchlists and email notifications. Both offer API and MCP access and fair monthly pricing.